The Forced Swim Test developed in 1977, models depression using mice or rats to screen for antidepressant medications. It has ...

The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...

The Gates Foundation-funded Gavi immunization programme introduced the GlaxoSmithKline (GSK) Mosquirix vaccine in three ...

The global tinea pedis treatment market is on a robust growth trajectory, projected to reach a market value of USD 2,484 ...

The new vaccine, GlaxoSmithKline’s Shingrix, is more than 90% effective in preventing shingles – and that, of course, is its goal. But this research suggests another unexpected advantage. The study ...

The Capital Structure page of GlaxoSmithKline Pharmaceuticals Ltd. presents the Authorized Capital, Issued Capital, and Paid-Up Equity Capital of the company over the period.

Vicebio has raised $100m in a Series B funding round led by TCGX. Credit: MargJohnsonVA via Shutterstock. UK-based startup ...

New Mechanistic Insights Underscore Multiple Potential Roles for Elraglusib as an Immune Modulator in the treatment of ...

Discover Vicebio's molecular clamp technology as it completes a $100 million series B round for its bivalent vaccine against ...

Tickets sold out so quickly for today’s Labour party conference “business day” that it was dubbed the corporate equivalent of ...

The company’s technology, which enables it to target viral proteins in their “prefusion” shape and skip a manufacturing step, could lead to vaccines that are more potent and easier to produce, said ...

Discover the potential of nature-based real assets for institutional investors. Learn how HSBC and Pollination's Climate Asset Management is leading the way.